Orbimed Advisors LLC Alpine Immune Sciences, Inc. Transaction History

Orbimed Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$17.75 - $41.6 $2.58 Million - $6.04 Million	145,251 Added 5.73%	2,680,496 $106 Million
Q4 2023 Feb 14, 2024	SELL	$8.54 - $20.22 $13.2 Million - $31.3 Million	-1,546,347 Reduced 37.89%	2,535,245 $48.3 Million
Q3 2021 Nov 15, 2021	BUY	$8.19 - $11.31 $8.28 Million - $11.4 Million	1,010,637 Added 32.91%	4,081,592 $43.6 Million
Q4 2020 Feb 16, 2021	SELL	$7.42 - $15.96 $4.45 Million - $9.58 Million	-600,000 Reduced 16.34%	3,070,955 $38.7 Million
Q1 2019 May 15, 2019	BUY	$4.09 - $7.19 $1.52 Million - $2.68 Million	372,439 Added 11.29%	3,670,955 $25.2 Million
Q3 2017 Nov 14, 2017	BUY	$8.0 - $11.6 $26.4 Million - $38.3 Million	3,298,516	3,298,516 $38.3 Million

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.